k75fiou6

Property	Value
?:abstract	Immune and inflammatory responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute to disease severity of coronavirus disease 2019 (COVID-19). However, the utility of specific immune-based biomarkers to predict clinical outcome remains elusive. Here, we analyzed levels of 66 soluble biomarkers in 175 Italian patients with COVID-19 ranging from mild/moderate to critical severity and assessed type I IFN–, type II IFN–, and NF-κB–dependent whole-blood transcriptional signatures. A broad inflammatory signature was observed, implicating activation of various immune and nonhematopoietic cell subsets. Discordance between IFN-α2a protein and IFNA2 transcript levels in blood suggests that type I IFNs during COVID-19 may be primarily produced by tissue-resident cells. Multivariable analysis of patients’ first samples revealed 12 biomarkers (CCL2, IL-15, soluble ST2 [sST2], NGAL, sTNFRSF1A, ferritin, IL-6, S100A9, MMP-9, IL-2, sVEGFR1, IL-10) that when increased were independently associated with mortality. Multivariate analyses of longitudinal biomarker trajectories identified 8 of the aforementioned biomarkers (IL-15, IL-2, NGAL, CCL2, MMP-9, sTNFRSF1A, sST2, IL-10) and 2 additional biomarkers (lactoferrin, CXCL9) that were substantially associated with mortality when increased, while IL-1α was associated with mortality when decreased. Among these, sST2, sTNFRSF1A, IL-10, and IL-15 were consistently higher throughout the hospitalization in patients who died versus those who recovered, suggesting that these biomarkers may provide an early warning of eventual disease outcome.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/k75fiou6_hasAnnotation_C1155266> <https://research.tib.eu/covid-19/entity/k75fiou6_hasAnnotation_C1332821> <https://research.tib.eu/covid-19/entity/k75fiou6_hasAnnotation_C1334080> <https://research.tib.eu/covid-19/entity/k75fiou6_hasAnnotation_C1514562> <https://research.tib.eu/covid-19/entity/k75fiou6_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Abers%2C_Michael_S.%3B_Delmonte%2C_Ottavia_M.%3B_Ricotta%2C_Emily_E.%3B_Fintzi%2C_Jonathan%3B_Fink%2C_Danielle_L.%3B_de_Jesus%2C_Adriana_A._Almeida%3B_Zarember%2C_Kol_A.%3B_Alehashemi%2C_Sara%3B_Oikonomou%2C_Vasileios%3B_Desai%2C_Jigar_V.%3B_Canna%2C_Scott_W.%3B_Shakoory%2C_Bita%3B_Dobbs%2C_Kerry%3B_Imberti%2C_Luisa%3B_Sottini%2C_Alessandra%3B_Quiros-Roldan%2C_Eugenia%3B_Castelli%2C_Francesco%3B_Rossi%2C_Camillo%3B_Brugnoni%2C_Duilio%3B_Biondi%2C_Andrea%3B_Bettini%2C_Laura_Rachele%3B_D%E2%80%99Angio%E2%80%99%2C_Mariella%3B_Bonfanti%2C_Paolo%3B_Castagnoli%2C_Riccardo%3B_Montagna%2C_Daniela%3B_Licari%2C_Amelia%3B_Marseglia%2C_Gian_Luigi%3B_Gliniewicz%2C_Emily_F.%3B_Shaw%2C_Elana%3B_Kahle%2C_Dana_E.%3B_Rastegar%2C_Andre_T.%3B_Stack%2C_Michael%3B_Myint-Hpu%2C_Katherine%3B_Levinson%2C_Susan_L.%3B_DiNubile%2C_Mark_J.%3B_Chertow%2C_Daniel_W.%3B_Burbelo%2C_Peter_D.%3B_Cohen%2C_Jeffrey_I.%3B_Calvo%2C_Katherine_R.%3B_Tsang%2C_John_S.%3B_Su%2C_Helen_C.%3B_Gallin%2C_John_I.%3B_Kuhns%2C_Douglas_B.%3B_Goldbach-Mansky%2C_Raphaela%3B_Lionakis%2C_Michail_S.%3B_Notarangelo%2C_Luigi_D.>
?:doi	10.1172/jci.insight.144455
?:doi	<https://research.tib.eu/covid-19/entity/10.1172/jci.insight.144455>
?:journal	JCI_insight
?:license	cc-by
?:pdf_json_files	document_parses/pdf_json/1e241652f0dd1dd5d27ce5fcfaaaa36b18ff9e85.json
?:pmc_json_files	document_parses/pmc_json/PMC7821609.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7821609>
?:pmid	<https://research.tib.eu/covid-19/entity/33232303.0>
?:pmid	33232303.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:sha_id	<https://research.tib.eu/covid-19/entity/1e241652f0dd1dd5d27ce5fcfaaaa36b18ff9e85>
?:source	Medline; PMC
?:title	An immune-based biomarker signature is associated with mortality in COVID-19 patients
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2021-01-11

Property

Value

?:abstract

Immune and inflammatory responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute to disease severity of coronavirus disease 2019 (COVID-19). However, the utility of specific immune-based biomarkers to predict clinical outcome remains elusive. Here, we analyzed levels of 66 soluble biomarkers in 175 Italian patients with COVID-19 ranging from mild/moderate to critical severity and assessed type I IFN–, type II IFN–, and NF-κB–dependent whole-blood transcriptional signatures. A broad inflammatory signature was observed, implicating activation of various immune and nonhematopoietic cell subsets. Discordance between IFN-α2a protein and IFNA2 transcript levels in blood suggests that type I IFNs during COVID-19 may be primarily produced by tissue-resident cells. Multivariable analysis of patients’ first samples revealed 12 biomarkers (CCL2, IL-15, soluble ST2 [sST2], NGAL, sTNFRSF1A, ferritin, IL-6, S100A9, MMP-9, IL-2, sVEGFR1, IL-10) that when increased were independently associated with mortality. Multivariate analyses of longitudinal biomarker trajectories identified 8 of the aforementioned biomarkers (IL-15, IL-2, NGAL, CCL2, MMP-9, sTNFRSF1A, sST2, IL-10) and 2 additional biomarkers (lactoferrin, CXCL9) that were substantially associated with mortality when increased, while IL-1α was associated with mortality when decreased. Among these, sST2, sTNFRSF1A, IL-10, and IL-15 were consistently higher throughout the hospitalization in patients who died versus those who recovered, suggesting that these biomarkers may provide an early warning of eventual disease outcome.

is ?:annotates of